Clinical trial

BnH-015B Clinical Trial in Moderate Alzheimer's Disease

NCT06535308

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-10-22

PhasePHASE1

Study timeline

Study start (actual)2024-10-22Date precision: day

Registry last updated2025-01-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alzheimer Diseaseunresolved

Interventions

BnH-015B 5 mgDRUG

BnH-015B 10 mgDRUG

BnH-015B 20 mgDRUG

BnH-015B 40 mg (Dietary impact)DRUG

BnH-015B 40 mgDRUG

BnH-015B 80 mgDRUG

BnH-015B 160 mgDRUG

BnH-015B 40 mg (MAD)DRUG

BnH-015B 80 mg (MAD)DRUG

BnH-015B 40 mg (Part II)DRUG

BnH-015B 80 mg (Part II)DRUG

BnH-015B Placebo (Part II)DRUG

Sponsors & collaborators

BnH Researchlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06535308 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.